Alnylam Pharmaceuticals' Profit After Tax rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
Latest data reveals that Alnylam Pharmaceuticals reported Profit After Tax of $251.1 million as of Q3 2025, which was up 478.84% from -$66.3 million recorded in Q2 2025.
Over the past 5 years, Alnylam Pharmaceuticals' Profit After Tax peaked at $251.1 million during Q3 2025, and registered a low of -$405.9 million during Q3 2022.
For the 3-year period, Alnylam Pharmaceuticals' Profit After Tax averaged around -$53.7 million, with its median value being -$66.3 million (2025).
Examining YoY changes over the last 5 years, Alnylam Pharmaceuticals' Profit After Tax showed a top increase of 325.05% in 2025 and a maximum decrease of 292.43% in 2025.
Alnylam Pharmaceuticals' Profit After Tax (Quarterly) stood at -$258.5 million in 2021, then increased by 19.72% to -$207.5 million in 2022, then spiked by 33.55% to -$137.9 million in 2023, then spiked by 39.24% to -$83.8 million in 2024, then skyrocketed by 325.05% to $251.1 million in 2025.
Its Profit After Tax stands at $251.1 million for Q3 2025, versus -$66.3 million for Q2 2025 and -$57.5 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value